Replies to post #629087 on NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

Biosect,

Roche has in the past first partnered with a company, then acquired it, but generally kept it operating as a Roche subsidiary. In the case of Genentech, they spun it off again and reacquired it.

I would prefer that sort of arrangement to a flat out buyout.

Gary

[extrooper]

Roche has failed at every clinical in past couple yrs. They are one more trying to build DCVax-L success by aggregate of buying smaller companies or biologic. They are as poorly managed as Merck and Pfizer with their death drugs.

[ilovetech]

You might want to consider rereading what I wrote, and read between the lines a bit. You see that's just it, there's never a shortage for excuses. If Roche's stock went up, and I said, "look, Roche's stock went up, they must have great management." Then the song would be, "That's silly, Roche is a big company, the market expects them to perform well." Let's be honest, it's precisely because NWBO is a small company, that this board felt like it was going into labor, everytime that one elusive milestone was thought to be the harbinger of greater highs, and numerous homeruns later, we went in the wrong direction. Of course it was criminal manipulation. I say, people can be, and have so far proven to be, let down, because they tend to put way too much expectation on a single catalyst. You just made a case for why it's not prudent to do so. In sum, I made a case for why LP hasn't spent her awakened days worrying about stroking shareholder expectations at a micro level, because she's too busy building a ginormous fly trap that will stick after the sting subsides.

ILT